Reflections and Future Directions in CLL Management

EP: 1.Recent Guideline Updates in the Frontline Management of CLL

EP: 2.Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

EP: 3.Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL Patients

EP: 4.Time-Limited Therapy with Venetoclax-Obinutuzumab: Rationale and Data

EP: 5.Clinical Insights and Real-World Evidence

EP: 6.Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines

EP: 7.Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTKi Options

EP: 8.Managing CLL with TP53 Mutation or del(17p): Guidelines and Strategies

EP: 9.Exploring Novel BCL2i and BTKi Combinations in Frontline CLL Therapy

EP: 10.Relapse After Venetoclax-Based Therapy: Early vs Late Management

EP: 11.Progression on BTK Inhibitors: Treatment Options and Considerations

EP: 12.Emerging Agents and Future Strategies in Relapsed/Refractory CLL

Now Viewing

EP: 13.Reflections and Future Directions in CLL Management

Video content above is prompted by the following:

• Briefly comment on the increasing preference for fixed-duration therapy over treatment until progression, as reflected in recent guideline updates:
  • How do you view the balance between fixed-duration and treat-to-progression approaches?
  • How might strategies continue to evolve, and what implications could it have for future treatment practices?

• Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at ASH 2024.
  Let’s consider what opportunities/what we are looking forward to ahead in 2025. Points to consider:
  • What accomplishments in CLL are you most proud of?
  • Which developments stand out as pivotal in shaping clinical practice?
  • What are you most excited about in 2025?
  • What areas are primed for significant progress? What do you hope to achieve in the coming year?